Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies

Cancer

Volumn 97, Issue 1, 2003, Pages 170-178

  Mekhail, Tarek ^a,b   Hutson, Thomas E ^a   Elson, Paul ^a   Budd, G Thomas ^a   Srkalovic, Gordon ^a   Olencki, Thomas ^a   Peereboom, David ^a   Pelley, Robert ^a   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Docetaxel; Gemcitabine; Phase I trial; Refractory malignancies

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; GEMCITABINE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG TOLERABILITY; EDEMA; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0037216197     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10991     Document Type: Article

References (61)

1. Francis PA, Rigas JR, Kris MG, et al. Phase II of docetaxel in patients with Stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12:1232-1237.
2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18: 2095-2103.
3. Fosella FV, DeVore R, Kerr RN, et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354-2362.
4. Anderson H, Lund B, Bach F, et al. Single-agent activity, of weekly gemcitabine in advanced non-small cell carcinoma: A Phase II study. J Clin Oncol. 1994;12:1821-1826.
5. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: A Phase II trial with gemcitabine. J Clin Oncol. 1995; 13:2731-2736.
6. Ravdin PM, Burris HA III, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995;13: 2879-2885.
7. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403-2413.
8. Rougier P. Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drugs. 1995; 6(Suppl 4):25-29.
9. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.J Clin Oncol. 1997;15:3394-3398.
10. McCaffery JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853-1857.
11. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol. 1996;63:89-93.
12. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994;12:2301-2308.
13. Plunket W, Huang P, Searcy CE, et al. Gemcitabine: Preclinical pharmacology and mechanism of action. Semin Oncol. 1996;23(Suppl 10):3-15.
14. Hennequinn C, Giocanti N, Favaudan V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronized HeLa cells. Br J Cancer. 1995;71:1194-1198.
15. Pawinski A, Louwerens M, Tonelli D, et al. A Phase I study of Taxotere (T) and Gemzar (G) in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 1998; 17:249a.
16. Spiridonidis CH, Laufman LR, Jones JJ, et al. Weekly gemcitabine (gem) combined with monthly docetaxel (doc) in patients (pts) with advanced malignancies. A Phase I trial. Ann Oncol. 2001;12:89-94.
17. Rebattu P, Pujol JL, Ardiet C, et al. Combination of docetaxel (T) and gemcitabine (G) in patients with, inoperable or metastatic non-small cell lung cancer (NSCLC), a Phase I study. Preliminary results on an active regimen [abstract]. Amsterdam: Tenth NCI-EORTC Symposium on New Drugs in Cancer Therapy, June, 1998.
18. Georgoulias V, Kouroussis C, Andoulakis N, et al. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: Preliminary results. Semin Oncol. 1977; 24(Suppl 14):S22-25.
19. Georgoulias V, Kouroussis C, Andoulakis N, et al. Front-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel (D) and gemcitabine (G): A multicenter Phase II trial. J Clin Oncol. 1999;17:914-920.
20. Davis TH, Rigas J, Maurer H, et al. Unique two week schedule of docetaxel and short infusion gemcitabine in solid tumors: Preliminary results of a Phase I trial [abstract]. Proc Am Soc Clin Oncol. 1998;17:239a.
21. Davis TH, Rigas J, Maurer H, et al. Phase I trial of docetaxel and short infusion gemcitabine given every two weeks for advanced solid tumors [abstract]. Ann Oncol. 1998;9(Suppl 4):S134.
22. Briasoulis E, Karavasilis V, Anastasopoulos D, et al. Weekly docetaxel in minimally pretreated cancer patients: A dose escalation study focused on feasibility and cumulative toxicity of long term administration. Ann Oncol. 1999;10:701-706.
23. Hainsworth JD, Burris HA, Erland JB, et al. Phase I of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
24. Luck HJ, Galaubitz M. Phase I study of weekly docetaxel (Taxotere) in heavily pretreated breast cancer patients. Eur J Cancer. 1997;33:S158.
25. Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer. 2001;92:2158-2163.
26. Hainsworth JD, Burris HA, Erland JB, et al. Phase I of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
27. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1996;14:1672-1678.
28. Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity, with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999;10:943-947.
29. Loëffler T, Freund W, Droge C, Hausamen T. Activity of weekly taxotere (TXT) in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1998;17:113a.
30. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
31. National Cancer Institute. Common Toxicity Criteria, Version 2.0. Bethesda: National Cancer Institute, 1998.
32. Millward MJ, Zaleberg J, Bishop JF, et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol. 1997;15: 750-758.
33. Shepherd FA, Burkes R, Cornier Y, et al. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose. J Clin Oncol. 1996; 14:1656-1662.
34. Georgoulias V, Papadakis E, Alexopolous A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicenter trial. Lancet. 2001;357:1478-1484.
35. Schlosser NJJ, Richel DJ, van Zanwijk N, et al. Phase I study of docetaxel and gemcitabine combination chemotherapy in chemotherapy naïve patients with advanced or metastatic non small lung cancer [abstract]. Proc Am Soc Clin Oncol. 1998;17:499a.
36. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol. 1994;12:1238-1244.
37. Zalcerg J, Milward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol. 1998;16:1948-1953.
38. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of taxotere (docetaxel), doxorubicin and cyclophosphamide (TAC) in the treatment of metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1997; 16:148a.
39. Burris HA. Optimal use of docetaxel (Taxotere): Maximizing its potential. Anticancer Drugs. 1996;7(Suppl 2):25-28.
40. Van Oosterom AT, Schrivjiers D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs. 1995;6:356-368.
41. Bhargava P, Marshall JL, Fried K, et al. Phase I and pharmacokinetics study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chem Pharm. 2001;48:95-103.
42. Frasci G, Comella P, D'Aiuto G, et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study. Southern Italy Cooperative Oncology Group (SIGOG). Ann Oncol. 2000;11: 367-371.
43. Ryan DP, Lynch TJ, Grossbard ML, et al. A Phase I study of gemcitabine and docetaxel patients with metastatic solid tumors. Cancer. 2000;88:180-185.
44. Rischin D, Boyer M, Smith J, et al. A Phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol. 2000;11:421-426.
45. Hejna M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger WCC, Marosi L. Treatment of patients with advanced non-small cell lung cancer using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer. 2000;89:516-522.
46. Pavikis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity, resulting from treatment with gemcitabine. Cancer. 1997;80:286-291.
47. Merad M, Le Cesne A, Baldeyrou P, et al. Docetaxel and interstitial pulmonary injury. Ann Oncol. 1997;8:191-194.
48. Hainsworth JD, Burris HA, Greco A. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol. 2000;28(Suppl 9):21-25.
49. Kououssis C, Agelaki S, Mavroudis D, et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2000;46:488-492.
50. Aventis Pharmaceutical Products, Inc. Taxatere Package Insert. Bridgewater, NJ: Aventis Pharmaceutical Products, Inc., 2000.
51. Harris J, Morrow M, Norton L. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, Principles and Practice of Oncology, 5th Ed. Philadelphia: Lippincott-Raven, 1997:1557-1616.
52. Gilewski T, Norton L. Cytokines of neoplasia. In: Mendelson J, Howley P, Israel MA, et al., editors. Molecular Basis of Cancer. Philadelphia: Saunders, 1995:143-159.
53. Norton L. Adjuvant breast cancer therapy: Current status and future strategies. Growth kinetics and the improved drug therapy of breast cancer. Semin Oncol. 1999;26(1 Suppl 3):1-4.
54. Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Bradof JE, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2000;89:328-333.
55. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18:1212-1219.
56. Akerley W, Choy H, Safran H, et al. Weekly paclitaxel in patients with advanced lung cancer. Semin Oncol. 1997;24: 10-13.
57. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administration weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997;15: 187-192.
58. Hahn SM, Liebman JE, Cook J, et al. Taxol in combination with doxorubicin or etoposide. Cancer, 1993;72:2705-2711.
59. Theodossiou C, Cook JA, Fisher J, et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol. 1998;12:217-222.
60. Zoli W, Ricotti L, Barzanti L, et al. Schedule dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer. 1999;80:413-416.
61. Zoli W, Ricotti L, Dal Susino M, et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer. 1999;81:609-615.